Stryker Corporation $SYK Shares Bought by Czech National Bank

Czech National Bank grew its position in shares of Stryker Corporation (NYSE:SYK) by 3.9% during the fourth quarter, HoldingsChannel reports. The firm owned 90,755 shares of the medical technology company’s stock after buying an additional 3,366 shares during the period. Czech National Bank’s holdings in Stryker were worth $31,898,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Armstrong Advisory Group Inc. grew its holdings in Stryker by 12.3% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 247 shares of the medical technology company’s stock valued at $91,000 after purchasing an additional 27 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in Stryker by 1.4% in the 3rd quarter. Venturi Wealth Management LLC now owns 1,904 shares of the medical technology company’s stock worth $704,000 after buying an additional 27 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in Stryker by 3.9% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 745 shares of the medical technology company’s stock valued at $275,000 after buying an additional 28 shares during the last quarter. Wolff Wiese Magana LLC grew its stake in shares of Stryker by 2.3% during the third quarter. Wolff Wiese Magana LLC now owns 1,271 shares of the medical technology company’s stock valued at $470,000 after acquiring an additional 28 shares in the last quarter. Finally, Lantz Financial LLC grew its stake in shares of Stryker by 5.0% during the third quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock valued at $225,000 after acquiring an additional 29 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Down 0.4%

Shares of NYSE SYK opened at $327.34 on Thursday. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average price is $361.50 and its two-hundred day moving average price is $364.58. Stryker Corporation has a 52-week low of $324.93 and a 52-week high of $404.87. The stock has a market capitalization of $125.37 billion, a P/E ratio of 38.97, a PEG ratio of 1.92 and a beta of 0.85.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same quarter last year, the firm earned $4.01 EPS. The business’s revenue was up 11.4% on a year-over-year basis. On average, analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s payout ratio is currently 41.90%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the company. BTIG Research boosted their price target on Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Raymond James Financial raised Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a report on Tuesday, January 6th. Jefferies Financial Group restated a “buy” rating and set a $465.00 price objective on shares of Stryker in a report on Wednesday, March 4th. Piper Sandler reiterated an “overweight” rating on shares of Stryker in a research note on Tuesday, January 27th. Finally, The Goldman Sachs Group set a $399.00 target price on Stryker in a research note on Friday, January 9th. Fourteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $427.50.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.